<DOC>
	<DOCNO>NCT00747604</DOCNO>
	<brief_summary>This project retrospective ( begin January 2006 ) prospective patient registry program sponsor Ipsen ( formerly Tercica , Inc. ) . In collaboration participate health care practitioner , patient registry program observational study monitor long-term safety patient treat Increlex® ( mecasermin [ rDNA origin ] injection ) . The IGFD ( Increlex® Growth Forum Database ) Registry intend primarily monitor safety efficacy Increlex replacement therapy child growth failure .</brief_summary>
	<brief_title>IGFD Registry : A Patient Registry Monitoring Long-term Safety Efficacy Increlex</brief_title>
	<detailed_description>The data collect patient exist patient 's medical record part standard medical care . No additional patient procedure activity mandate study . The specific data collect visit schedule data collection list schedule assessment . The collection safety event consider essential Registry . The website provide opportunity report occurrence target adverse event ( AEs ) , important event consider related Increlex administration serious adverse event ( SAEs ) .</detailed_description>
	<criteria>Parents legally authorize representative must give sign informed consent Registryrelated activity conduct . Assent subject also obtain appropriate . Patients receive Increlex® qualify practitioner may enrol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Growth Hormone ( GH ) Insensitivity Syndrome</keyword>
	<keyword>Insulin-like Growth Factor Deficiency ( IGFD )</keyword>
	<keyword>Short Stature</keyword>
	<keyword>Insulin-like Growth Factor ( IGF-1 )</keyword>
	<keyword>Growth</keyword>
</DOC>